Related Experiment Video
Updated: Jun 16, 2025
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
Published on: February 17, 2023
Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment
Yuxuan Tu1, Jianbao Gong2, Jing Mou3
1The Afffliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Abstract:
Approved anticancer drugs typically face challenges due to their narrow therapeutic window, primarily because of high systemic toxicity and limited selectivity for tumors. Prodrugs are initially inactive drug molecules designed to undergo specific chemical modifications. These modifications render the drugs inactive until they encounter specific conditions or biomarkers in vivo, at which point they are converted into active drug molecules. This thoughtful design significantly improves the efficacy of anticancer drug delivery by enhancing tumor specificity and minimizing off-target effects. Recent advancements in prodrug design have focused on integrating these strategies with delivery systems like liposomes, micelles, and polymerosomes to further improve targeting and reduce side effects. This review outlines strategies for designing stimuli-responsive small molecule prodrugs focused on cancer treatment, emphasizing their chemical structures and the mechanisms controlling drug release. By providing a comprehensive overview, we aim to highlight the potential of these innovative approaches to revolutionize cancer therapy.
Insights
This review explores stimuli-responsive prodrugs for cancer treatment. These smart drug delivery systems improve tumor targeting and reduce side effects, offering a promising approach to enhance anticancer therapies.
Area of Science:
- Oncology
- Medicinal Chemistry
- Drug Delivery Systems
Background:
- Approved anticancer drugs often exhibit narrow therapeutic windows due to systemic toxicity and poor tumor selectivity.
- Prodrugs are inactive drug precursors that are converted to active agents specifically within the body, enhancing therapeutic outcomes.
- Current research integrates prodrug strategies with advanced delivery systems to improve cancer treatment efficacy.
Purpose of the Study:
- To review strategies for designing stimuli-responsive small molecule prodrugs for cancer therapy.
- To emphasize the chemical structures and release mechanisms of these prodrugs.
- To highlight the potential of prodrugs to revolutionize cancer treatment through improved targeting and reduced toxicity.
Main Methods:
- Review of existing literature on stimuli-responsive prodrug design for cancer.
- Analysis of chemical structures and activation mechanisms of prodrugs.
- Exploration of integration with drug delivery systems like liposomes and micelles.
Main Results:
- Stimuli-responsive prodrugs offer enhanced tumor specificity and reduced off-target effects.
- Specific chemical modifications and *in vivo* conditions trigger prodrug activation.
- Integration with delivery systems further optimizes drug release and localization.
Conclusions:
- Stimuli-responsive prodrugs represent a significant advancement in anticancer drug delivery.
- These innovative approaches have the potential to improve treatment efficacy and patient outcomes.
- Further development in prodrug design could revolutionize cancer therapy.
Related Concept Videos
01:30Prodrugs
Prodrugs help overcome...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Drug Discovery: Overview